Published in J Biol Chem on November 30, 2015
Inference of macromolecular assemblies from crystalline state. J Mol Biol (2007) 44.95
The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem (2001) 4.81
P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation (2008) 2.66
Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem (2009) 2.19
An overview of the serpin superfamily. Genome Biol (2006) 2.14
Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient mice. Circulation (2003) 2.11
Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation (1996) 1.86
A redox switch in angiotensinogen modulates angiotensin release. Nature (2010) 1.50
Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry (2002) 1.23
Serpins: structure, function and molecular evolution. Int J Biochem Cell Biol (2003) 1.17
Platelet-fibrinogen interactions. Ann N Y Acad Sci (2001) 1.14
BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat Commun (2011) 1.11
Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol (2002) 1.10
β-catenin/TCF-1 pathway in T cell development and differentiation. J Neuroimmune Pharmacol (2012) 0.97
The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochem Biophys Res Commun (2006) 0.97
The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. Adv Exp Med Biol (2009) 0.94
Partially glycosylated dendrimers block MD-2 and prevent TLR4-MD-2-LPS complex mediated cytokine responses. PLoS Comput Biol (2011) 0.93
Molecular basis for proline- and arginine-rich peptide inhibition of proteasome. J Mol Biol (2008) 0.92
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. J Biol Chem (2006) 0.90
A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Circ Cardiovasc Interv (2010) 0.90
Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B. J Leukoc Biol (2008) 0.90
BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis. J Thorac Cardiovasc Surg (2013) 0.89
Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways. Thromb Haemost (2006) 0.89
Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J Biol Chem (2003) 0.86
Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. Thromb Haemost (2010) 0.86
Proteolytic activation transforms heparin cofactor II into a host defense molecule. J Immunol (2013) 0.85
Myxomavirus-derived serpin prolongs survival and reduces inflammation and hemorrhage in an unrelated lethal mouse viral infection. Antimicrob Agents Chemother (2013) 0.83
Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Biomaterials (2013) 0.83
Calreticulin, a potential vascular regulatory protein, reduces intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol (1997) 0.83
Induction of indefinite cardiac allograft survival correlates with toll-like receptor 2 and 4 downregulation after serine protease inhibitor-1 (Serp-1) treatment. Transplantation (2007) 0.82
Hapivirins and diprovirins: novel θ-defensin analogs with potent activity against influenza A virus. J Immunol (2012) 0.82
Increased circulating monocyte activation in patients with unstable coronary syndromes. J Am Coll Cardiol (2001) 0.81
Prevention of chronic renal allograft rejection by SERP-1 protein. Transplantation (2006) 0.81
Viral serpin therapeutics from concept to clinic. Methods Enzymol (2011) 0.80
Enantiomeric 9-mer peptide analogs of protaetiamycine with bacterial cell selectivities and anti-inflammatory activities. J Pept Sci (2011) 0.79
C-terminal apolipoprotein E-derived peptide, Ep1.B, displays anti-atherogenic activity. Atherosclerosis (2006) 0.79
Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro. PLoS One (2012) 0.79
Reductions in mRNA of the neuroprotective agent, neuroserpin, after cerebral ischemia/reperfusion in diabetic rats. Brain Res (2004) 0.79
The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin. Thromb Haemost (2007) 0.78
Alanine scan of an immunosuppressive peptide (CP): analysis of structure-function relationships. Chem Biol Drug Des (2012) 0.77
Fluorescence spectroscopic analysis of circulating platelet activation during coronary angioplasty. Lasers Surg Med (2001) 0.77
Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity. Bioorg Med Chem Lett (2012) 0.77